<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Inform</journal-id>
    <journal-id journal-id-type="publisher-id">CIX</journal-id>
    <journal-id journal-id-type="hwp">spcix</journal-id>
    <journal-title-group>
      <journal-title>Cancer Informatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1176-9351</issn>
    <publisher>
      <publisher-name>SAGE Publications</publisher-name>
      <publisher-loc>Sage UK: London, England</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9549197</article-id>
    <article-id pub-id-type="doi">10.1177/11769351221127875</article-id>
    <article-id pub-id-type="publisher-id">10.1177_11769351221127875</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software or Database Review</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SurviveAI: Long Term Survival Prediction of Cancer Patients Based on
Somatic RNA-Seq Expression</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5060-891X</contrib-id>
        <name>
          <surname>Nayshool</surname>
          <given-names>Omri</given-names>
        </name>
        <xref rid="aff1-11769351221127875" ref-type="aff">1</xref>
        <xref rid="aff2-11769351221127875" ref-type="aff">2</xref>
        <xref rid="corresp1-11769351221127875" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kol</surname>
          <given-names>Nitzan</given-names>
        </name>
        <xref rid="aff1-11769351221127875" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Javaski</surname>
          <given-names>Elisheva</given-names>
        </name>
        <xref rid="aff1-11769351221127875" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Amariglio</surname>
          <given-names>Ninette</given-names>
        </name>
        <xref rid="aff1-11769351221127875" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rechavi</surname>
          <given-names>Gideon</given-names>
        </name>
        <xref rid="aff1-11769351221127875" ref-type="aff">1</xref>
        <xref rid="aff2-11769351221127875" ref-type="aff">2</xref>
      </contrib>
    </contrib-group>
    <aff id="aff1-11769351221127875"><label>1</label>Bioinformatics Unit, Sheba Cancer
Research Center and Wohl Institute for Translational Medicine, Sheba Medical Center,
Tel HaShomer, Israel</aff>
    <aff id="aff2-11769351221127875"><label>2</label>Human Molecular Genetics and
Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel</aff>
    <author-notes>
      <corresp id="corresp1-11769351221127875">Omri Nayshool, Sheba Cancer Research
Center, Sheba Medical Center, Tel HaShomer, Derech Sheba 2, Ramat Gan 52621,
Israel. Email: <email>omri.nayshool@sheba.gov.il</email></corresp>
      <corresp id="corresp2-11769351221127875">Gideon Rechavi, Sheba Cancer Research
Center, Sheba Medical Center, Tel HaShomer, Derech Sheba 2, Ramat Gan 52621,
Israel. Email: <email>Gidi.Rechavi@sheba.health.gov.il</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>7</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>21</volume>
    <elocation-id>11769351221127875</elocation-id>
    <history>
      <date date-type="received">
        <day>25</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>5</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <sec id="section1-11769351221127875">
        <title>Motivation:</title>
        <p>Prediction of cancer outcome is a major challenge in oncology and is
essential for treatment planning. Repositories such as The Cancer Genome
Atlas (TCGA) contain vast amounts of data for many types of cancers. Our
goal was to create reliable prediction models using TCGA data and validate
them using an external dataset.</p>
      </sec>
      <sec id="section2-11769351221127875">
        <title>Results:</title>
        <p>For 16 TCGA cancer type cohorts we have optimized a Random Forest prediction
model using parameter grid search followed by a backward feature elimination
loop for dimensions reduction. For each feature that was removed, the model
was retrained and the area under the curve of the receiver operating
characteristic (AUC-ROC) was calculated using test data. Five prediction
models gave AUC-ROC bigger than 80%. We used Clinical Proteomic Tumor
Analysis Consortium v3 (CPTAC3) data for validation. The most enriched
pathways for the top models were those involved in basic functions related
to tumorigenesis and organ development. Enrichment for 2 prediction models
of the TCGA-KIRP cohort was explored, one with 42 genes (AUC-ROC = 0.86) the
other is composed of 300 genes (AUC-ROC = 0.85). The most enriched networks
for both models share only 5 network nodes: DMBT1, IL11, HOXB6, TRIB3, PIM1.
These genes play a significant role in renal cancer and might be used for
prognosis prediction and as candidate therapeutic targets.</p>
      </sec>
      <sec id="section3-11769351221127875">
        <title>Availability And Implementation:</title>
        <p>The prediction models were created and tested using Python SciKit-Learn
package. They are freely accessible via a friendly web interface we called
surviveAI at <ext-link xlink:href="https://tinyurl.com/survivea" ext-link-type="uri">https://tinyurl.com/survivea</ext-link>i.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>Cancer survivors</kwd>
      <kwd>supervised machine learning</kwd>
      <kwd>gene expression</kwd>
      <kwd>classification</kwd>
      <kwd>molecular targeted therapy</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>January-December 2022</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>typesetter</meta-name>
        <meta-value>ts1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="section4-11769351221127875">
    <title>Introduction</title>
    <p>Cancer is a leading cause of death, and accounts for 17% of mortality worldwide.
According to a report from the International Agency for Research on Cancer (IARC),
in 2018 a total of 9.5 million deaths and 18 million new cases of cancer were
reported worldwide. Interestingly, incidence and mortality rates are higher in men
and in the developed world.<sup><xref rid="bibr1-11769351221127875" ref-type="bibr">1</xref></sup> While some types of cancers are treated based on biomarkers
and specific genetic mutations,<sup><xref rid="bibr1-11769351221127875" ref-type="bibr">1</xref>,<xref rid="bibr2-11769351221127875" ref-type="bibr">2</xref></sup> most cases are still treated
according to specific guidelines by surgery, chemotherapy, and/or radiotherapy based
on data integrating the clinical, histopathological, details of therapy, imaging,
and outcome information of the patients.</p>
    <p>Accurate prediction of prognosis of the various subtypes of cancer may improve
tailoring of therapy by allowing to take into consideration the expected outcome
versus therapy choice, intensity, risk, side effects, and late complications.</p>
    <p>In the last decade, large OMICs databases were created that contain data generated
from thousands of cancer samples. The largest one, The Cancer Genome Atlas (TCGA), a
repository that contains genomic, epigenomic, transcriptomic, proteomic, and
clinical data, characterizing 33 types of tumors from over 20,000 patients, is
considered to be one of the largest sources for cancer OMICs data. Many groups have
tried to use TCGA data to predict the prognosis of patients affected by various
tumors using machine learning approaches, with varying levels of success.<sup><xref rid="bibr3-11769351221127875" ref-type="bibr">3</xref><xref rid="bibr4-11769351221127875" ref-type="bibr"/><xref rid="bibr5-11769351221127875" ref-type="bibr"/><xref rid="bibr6-11769351221127875" ref-type="bibr"/><xref rid="bibr7-11769351221127875" ref-type="bibr"/>-<xref rid="bibr8-11769351221127875" ref-type="bibr">8</xref></sup></p>
    <p>Random Forest<sup><xref rid="bibr9-11769351221127875" ref-type="bibr">9</xref></sup>
is a simple yet effective Machine Learning algorithm that proved to be a successful
predictor when using structured data such as RNA expression analysis.<sup><xref rid="bibr10-11769351221127875" ref-type="bibr">10</xref></sup> It has low
overfitting and a simple feature importance scoring function that is based on the
Mean Decrease in Impurity function (Gini Importance). This allows refinement of
prediction models and adds important insights into the biological role of each
feature in cancer development and prognosis.</p>
    <p>Cancer outcome prediction using OMICS-related data evolved in the last 2 decades
starting with the use of gene-expression microarrays.<sup><xref rid="bibr11-11769351221127875" ref-type="bibr">11</xref>,<xref rid="bibr12-11769351221127875" ref-type="bibr">12</xref></sup> The accumulation of data from
various OMICS technologies calls for the development of advanced cancer outcome
prediction tools.</p>
    <p>Here we describe a robust and simple analysis prediction tool using the Random Forest
algorithm on 5 tumor types using the TCGA database.</p>
  </sec>
  <sec sec-type="methods" id="section5-11769351221127875">
    <title>Methods</title>
    <sec id="section6-11769351221127875">
      <title>Data</title>
      <p>All RNA-seq datasets were downloaded from Genomic Data Commons (GDC). Clinical
data was downloaded from the firehose data portal. The RNA-seq FPKM-UQ
normalized data for cancer types of the TCGA projects were downloaded from
National Cancer Institute’s Genomic Data Commons data portal. The samples in
each project were divided into 2 groups. The first group included samples from
patients who were tumor-free for over 3 years (Tumor-Free samples), the second
group included samples from patients that succumbed to the disease at any time
point (Deceased group). We only used projects where the ratio between group size
and the total number of samples was between 20% and 80% (<xref rid="table1-11769351221127875" ref-type="table">Table 1</xref>). Validation of the models was
done using 2 datasets from Clinical Proteomic Tumor Analysis Consortium
v3(CPTAC3): Clear Cell Renal Cell Carcinoma (CPTAC3-ccRCC) and Uterine Corpus
Endometrial Carcinoma (CPTAC3-UCEC).</p>
      <table-wrap position="float" id="table1-11769351221127875">
        <label>Table 1.</label>
        <caption>
          <p>Samples summary for each TCGA project for total samples in the cohort and
samples with RNA-seq data. The Area Under the Curve of Receiver
Operating Characteristic curve (AUC-ROC) mean for the last 500 models
(500 to 1 features) was calculated for each project. The bold lines are
the models that scored averaged AUC-ROC of above 0.8. The CPTAC3-ccRCC
and CPTAC3-UCEC data were tested on the selected model with the minimal
number of features for each project and the AUC-ROC was calculated
respectively.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="10.1177_11769351221127875-table1" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th rowspan="1" colspan="1"/>
                <th align="left" colspan="3" rowspan="1">TCGA samples</th>
                <th align="left" colspan="3" rowspan="1">Samples with available RNA-seq
data</th>
                <th align="left" rowspan="1" colspan="1">AUC-ROC average (top 500 models)</th>
                <th align="left" rowspan="1" colspan="1">AUC-ROC CPTAC3-ccRCC</th>
                <th align="left" rowspan="1" colspan="1">AUC-ROC CPTAC3-UCEC</th>
                <th align="left" rowspan="1" colspan="1">Number of final selected model features</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Project</td>
                <td rowspan="1" colspan="1">Cancer type</td>
                <td rowspan="1" colspan="1">Tumor-free</td>
                <td rowspan="1" colspan="1">Deceased</td>
                <td rowspan="1" colspan="1">Tumor-free/Total</td>
                <td rowspan="1" colspan="1">Tumor-free</td>
                <td rowspan="1" colspan="1">Deceased</td>
                <td rowspan="1" colspan="1">Tumor-free/Total</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-HNSC</td>
                <td rowspan="1" colspan="1">Head and neck squamous cell carcinoma</td>
                <td rowspan="1" colspan="1">50</td>
                <td rowspan="1" colspan="1">170</td>
                <td rowspan="1" colspan="1">0.23</td>
                <td rowspan="1" colspan="1">47</td>
                <td rowspan="1" colspan="1">166</td>
                <td rowspan="1" colspan="1">0.221</td>
                <td rowspan="1" colspan="1">0.72</td>
                <td rowspan="1" colspan="1">0.50</td>
                <td rowspan="1" colspan="1">0.34</td>
                <td rowspan="1" colspan="1">30</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>TCGA-LGG</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Brain lower grade glioma</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>28</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>92</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.23</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>27</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>91</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.229</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.92</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.52</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.45</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>90</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-LUSC</td>
                <td rowspan="1" colspan="1">Lung squamous cell carcinoma</td>
                <td rowspan="1" colspan="1">49</td>
                <td rowspan="1" colspan="1">161</td>
                <td rowspan="1" colspan="1">0.23</td>
                <td rowspan="1" colspan="1">49</td>
                <td rowspan="1" colspan="1">157</td>
                <td rowspan="1" colspan="1">0.238</td>
                <td rowspan="1" colspan="1">0.55</td>
                <td rowspan="1" colspan="1">0.53</td>
                <td rowspan="1" colspan="1">0.42</td>
                <td rowspan="1" colspan="1">29</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-LUAD</td>
                <td rowspan="1" colspan="1">Lung adenocarcinoma</td>
                <td rowspan="1" colspan="1">39</td>
                <td rowspan="1" colspan="1">127</td>
                <td rowspan="1" colspan="1">0.23</td>
                <td rowspan="1" colspan="1">36</td>
                <td rowspan="1" colspan="1">125</td>
                <td rowspan="1" colspan="1">0.224</td>
                <td rowspan="1" colspan="1">0.75</td>
                <td rowspan="1" colspan="1">0.62</td>
                <td rowspan="1" colspan="1">0.30</td>
                <td rowspan="1" colspan="1">47</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-READ</td>
                <td rowspan="1" colspan="1">Rectum adenocarcinoma</td>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1">9</td>
                <td rowspan="1" colspan="1">0.25</td>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1">8</td>
                <td rowspan="1" colspan="1">0.273</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>TCGA-COAD</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Colon adenocarcinoma</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>20</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>57</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.26</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>19</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>56</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.253</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.84</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.64</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.69</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>12</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-LIHC</td>
                <td rowspan="1" colspan="1">Liver hepatocellular carcinoma</td>
                <td rowspan="1" colspan="1">32</td>
                <td rowspan="1" colspan="1">91</td>
                <td rowspan="1" colspan="1">0.26</td>
                <td rowspan="1" colspan="1">32</td>
                <td rowspan="1" colspan="1">88</td>
                <td rowspan="1" colspan="1">0.267</td>
                <td rowspan="1" colspan="1">0.67</td>
                <td rowspan="1" colspan="1">0.66</td>
                <td rowspan="1" colspan="1">0.49</td>
                <td rowspan="1" colspan="1">99</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>TCGA-SARC</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Sarcoma</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>33</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>76</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.30</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>33</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>74</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.308</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.86</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.85</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.74</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>36</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-BLCA</td>
                <td rowspan="1" colspan="1">Bladder urothelial carcinoma</td>
                <td rowspan="1" colspan="1">49</td>
                <td rowspan="1" colspan="1">109</td>
                <td rowspan="1" colspan="1">0.31</td>
                <td rowspan="1" colspan="1">48</td>
                <td rowspan="1" colspan="1">107</td>
                <td rowspan="1" colspan="1">0.310</td>
                <td rowspan="1" colspan="1">0.76</td>
                <td rowspan="1" colspan="1">0.54</td>
                <td rowspan="1" colspan="1">0.50</td>
                <td rowspan="1" colspan="1">50</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-SKCM</td>
                <td rowspan="1" colspan="1">Skin cutaneous melanoma</td>
                <td rowspan="1" colspan="1">84</td>
                <td rowspan="1" colspan="1">156</td>
                <td rowspan="1" colspan="1">0.35</td>
                <td rowspan="1" colspan="1">84</td>
                <td rowspan="1" colspan="1">154</td>
                <td rowspan="1" colspan="1">0.353</td>
                <td rowspan="1" colspan="1">0.70</td>
                <td rowspan="1" colspan="1">0.51</td>
                <td rowspan="1" colspan="1">0.43</td>
                <td rowspan="1" colspan="1">63</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>TCGA-CESC</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Cervical squamous cell carcinoma and endocervical
adenocarcinoma</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>53</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>60</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.47</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>53</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>59</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.473</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.81</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.69</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.60</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>83</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-KIRC</td>
                <td rowspan="1" colspan="1">Kidney renal clear cell carcinoma</td>
                <td rowspan="1" colspan="1">159</td>
                <td rowspan="1" colspan="1">162</td>
                <td rowspan="1" colspan="1">0.50</td>
                <td rowspan="1" colspan="1">157</td>
                <td rowspan="1" colspan="1">157</td>
                <td rowspan="1" colspan="1">0.500</td>
                <td rowspan="1" colspan="1">0.79</td>
                <td rowspan="1" colspan="1">0.77</td>
                <td rowspan="1" colspan="1">0.65</td>
                <td rowspan="1" colspan="1">96</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>TCGA-KIRP</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Kidney renal papillary cell carcinoma</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>39</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>32</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.55</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>37</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>32</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.536</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.88</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.86</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>0.71</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>42</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-BRCA</td>
                <td rowspan="1" colspan="1">Breast invasive carcinoma</td>
                <td rowspan="1" colspan="1">193</td>
                <td rowspan="1" colspan="1">104</td>
                <td rowspan="1" colspan="1">0.65</td>
                <td rowspan="1" colspan="1">191</td>
                <td rowspan="1" colspan="1">104</td>
                <td rowspan="1" colspan="1">0.647</td>
                <td rowspan="1" colspan="1">0.71</td>
                <td rowspan="1" colspan="1">0.30</td>
                <td rowspan="1" colspan="1">0.34</td>
                <td rowspan="1" colspan="1">99</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-UCEC</td>
                <td rowspan="1" colspan="1">Uterine corpus endometrial carcinoma</td>
                <td rowspan="1" colspan="1">94</td>
                <td rowspan="1" colspan="1">45</td>
                <td rowspan="1" colspan="1">0.68</td>
                <td rowspan="1" colspan="1">93</td>
                <td rowspan="1" colspan="1">44</td>
                <td rowspan="1" colspan="1">0.679</td>
                <td rowspan="1" colspan="1">0.72</td>
                <td rowspan="1" colspan="1">0.75</td>
                <td rowspan="1" colspan="1">0.63</td>
                <td rowspan="1" colspan="1">19</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="section7-11769351221127875">
      <title>Software</title>
      <p>We used python 3.7.6 and dependencies for full data analysis. Random Forest
classifiers were created using scikit-learn 0.23.2. Data parsing and analysis
were done using pandas 1.1.1. Ingenuity Pathway Analysis was used for network
enrichment assessments. The webapp was created based on Flask 1.1.2 and Jinja2
2.11.2.</p>
    </sec>
    <sec id="section8-11769351221127875">
      <title>Random forest model training and testing</title>
      <p>Dimension reduction for the model required several steps as illustrated in <xref rid="fig1-11769351221127875" ref-type="fig">Figure 1</xref>. The first RF
model for each TCGA project was created using all 65 483 mRNA features. The
model parameters were selected using GridSearchCV module from scikit-learn,
which tests all possible combinations from the provided list as detailed in
<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/11769351221127875" ext-link-type="uri">Supplemental Table 2</ext-link>. After the model training, the features
were scored and sorted using the model’s property
<italic toggle="yes">feature_importances_</italic>. The features with no importance
(score 0) were removed. With the rest of the features, we have built a second
model using a second GridSearchCV parameter search. The features were sorted and
scored, and again features with no importance (score 0) were removed. We have
continued dimensionality reduction using a backward feature elimination
loop,<sup><xref rid="bibr13-11769351221127875" ref-type="bibr">13</xref></sup> until only one feature was left. For each reduction (N−1),
each TCGA model was trained using 70% of the samples. The Area Under the Curve
of the Receiver Operating Characteristic (AUC-ROC) was calculated using the
predictions made on the testing data (the remaining 30% of the TCGA samples).
<xref rid="fig2-11769351221127875" ref-type="fig">Figure 2</xref> shows that
the optimal model that was selected was the one in where the minimal features
provided the average AUC-ROC of the last 500 modes.</p>
      <fig position="float" id="fig1-11769351221127875">
        <label>Figure 1.</label>
        <caption>
          <p>Model generation workflow for each TCGA project.</p>
        </caption>
        <graphic xlink:href="10.1177_11769351221127875-fig1" position="float"/>
      </fig>
      <table-wrap position="float" id="table2-11769351221127875">
        <label>Table 2.</label>
        <caption>
          <p>The selected TCGA modes features were analyzed using Ingenuity Pathway
Analysis (IPA) software for enriched networks. Only significant results
(<italic toggle="yes">P</italic>-value &lt; 10^−20) are shown. The networks
molecules and observed function are shown. For the TCGA-CESC features
list, there were 2 matched networks with a different but related
function.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="10.1177_11769351221127875-table2" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Project model</th>
                <th align="left" rowspan="1" colspan="1">Models features (order by significance)</th>
                <th align="left" rowspan="1" colspan="1">Pathway nodes</th>
                <th align="left" rowspan="1" colspan="1">Pathway score</th>
                <th align="left" rowspan="1" colspan="1">Molecules in pathways</th>
                <th align="left" rowspan="1" colspan="1">Pathway function</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">TCGA-KIRP</td>
                <td rowspan="1" colspan="1">DMBT1, RHEBL1, AC1448313, RP11_665C166, TOX2, IL11, GBP1P1,
FAM83D, NLRP9P1, PLCB3, PROX1-AS1, RP3_337H46, HOXB6, FGD5,
RP11_83N96, RP11_395L1417, LOC105375267, RP11_627K111, CUX1,
ZSWIM1, RP11_214N155, TBL1XR1, MDS2, IL20RB, TPM2,
RP11_134K12, LINC01108, RP11_181B111, AC0921714, KRT8P5,
PLBD2, RP11_427P53, LZTS3, RP11_466P246, E2F8, TRIB3,
LINC01358, GABBR2, RAP2C-AS1, NPAS1, PIM1, RP11_553N16,</td>
                <td rowspan="1" colspan="1">Akt, ANGPT4, CCND1, CDKN1B, CSTB, CUX1, DMBT1, E2F8, ERK,
ERK1/2, FAM83D, GABBR2, GBP1P1, HAPLN3, Histone h3, HOXB6,
IL11, IL20RB, Lh, LRRTM2, MOSPD2, NFkB (complex), PIM1,
PLCB3, SMARCA4, STAB2, STAT1, TBL1XR1, TBX21, TMEM204, TOX2,
TPM2, TRIB3, USPL1, WNT8B</td>
                <td rowspan="1" colspan="1">10^−38</td>
                <td rowspan="1" colspan="1">15</td>
                <td rowspan="1" colspan="1">[Cell cycle, connective tissue development and function,
renal and urological system development and function]</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">TCGA-CESC</td>
                <td rowspan="2" colspan="1">PIP4P2, LOC102724050, P4HA2, LINC01152, HENMT1,
RP5_882O71, PLAAT2, RPS19P1, RBM38, PTMAP10, DNAJC9-AS1,
DAAM2-AS1, mir-210, EREG, FNDC4, TMEM253, ANKRD37, ARHGEF25,
ESM1, NPY1R, SLC10A3, EEF1E1, MMP8, RP11_447H194,
RP11_45A174, SERPINH1, ITGA5, FOXC2, CTB_193M123, BAIAP2L1,
FUT11, VEGFA, ANXA5, ANKRD20A11P, ENPEP, RP11_89F32,
FUNDC2P1, RPSAP5, TMEM120B, UBAC1, COL4A2, LATS2,
RP11_378A132, RP11_598F75, PTTG3P, EPN2, SLN, TMEM138,
ABHD1, SEPSECS-AS1, SLC19A3, BCORL1, ZNF696, TXNP6,
WASHC2A/WASHC2C, CHST14, MATN3, MPRIP, KCND2, RP11_107F64,
MMP1, BCO1, SLC35A4, LINC00460, H3P36, APEX2, ANKRD34B,
CTRB2, GCOM1, LRRN4, SPON1, RP11_455F54, MMP3, LOC105378645,
PTPRB, ITGAD, ITGAV, SCN2A, GLUL, ANGPTL6,</td>
                <td rowspan="1" colspan="1">ARHGEF25, BAIAP2L1, CPS1, E2F3, EBAG9, EEF1E1, ENPEP, EPN2,
FUT1, FUT11, GLUL, HENMT1, HLA-J, HNF1A, HNMT, ITGAD, ITGB2,
LATS2, mir-210, MLF2, MMP8, MPRIP, NINJ1, NR3C1, PLEKHF1,
PPP1R14C, RHOA, SCO2, SERPINH1, SMARCA4, SON, SRC, TNF,
TP53, YWHAG</td>
                <td rowspan="1" colspan="1">10^−28</td>
                <td rowspan="1" colspan="1">14</td>
                <td rowspan="1" colspan="1">[Cardiovascular system development and function, organismal
injury and abnormalities, reproductive system disease]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">ABLIM, Akt, ANXA5, CG, COL4A2, EREG, ERK, ERK1/2, ESM1,
estrogen receptor, FOXC2, FSH, GNRH, IRS, ITGA5, ITGAV, Jnk,
Lh, MAP4K4, MMP1, MMP3, MT3, NFkB (complex), P38 MAPK,
P4HA2, Pdgf (complex), PDGF BB, PDXK, POP5, PTPRB, RBM38,
REXO5, SRD5A2, TLK1, VEGFA</td>
                <td rowspan="1" colspan="1">10^−25</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">[Dermatological diseases and conditions, inflammatory
disease, inflammatory response]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-SARC</td>
                <td rowspan="1" colspan="1">NMU, B4GALT2, SHOC2, RNU2-22P, MON1B, HNRNPR, ARHGAP28,
NDST2, ZFYVE28, ZNF146, SFTA2, RBM48, ARMCX3, ADCY1, QSER1,
POR, BTF3L4, LINC01121, ERI3, RP11_680G244, COPG1, BLOC1S6,
RAB5B, ELOVL2, DPP9-AS1, HPS6, ISCU, RPL29P19, TENT2, ARMH3,
JRKL, NKX6-1, AC241585.1, FEM1AP2, NFKB2, ACOX, '</td>
                <td rowspan="1" colspan="1">ACOX1, ARHGAP28, BLOC1S6, CCND1, CLEC11A, COPG1, DHRS2,
ERK1/2, HNRNPR, HPS6, HSPA1L, HSPA2, ISCU, JKAMP, KHDRBS1,
LATS, miR-515-3p (and other miRNAs w/seed AGUGCCU), MLF2,
MYB, NFkB (complex), NFKB2, NMU, POR, RAB22A, RPTOR,
SH3GLB2, SHOC2, SLC9B2, STAB2, TFAP2A, TGM2, TIMM8A, TP53,
TRIM6, ZNF146</td>
                <td rowspan="1" colspan="1">10^−28</td>
                <td rowspan="1" colspan="1">12</td>
                <td rowspan="1" colspan="1">[Cell cycle, cell death and survival, cellular
development]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-LGG</td>
                <td rowspan="1" colspan="1">RP11_13N135, RP11_10C243, LOC101929494, SP7, RP11_54O71,
MAN1B1-DT, ACTR1A, SPATA17, LOC105372974, AQP7, RP11_394B25,
RP11_14C103, HOMER2, LINC01521, RP11_330H66, BEX4, SORT1,
RP11_141O111, LOC100287042, BOK-AS1, MGC16275, CTC_498J121,
STARD9, TMEM67, LOC101928982, SPINK5, HINT3, INPPL1,
NUTM2A-AS1, KLF2, RPL39P36, RP1_196A121, RNU6-453P,
AC1456762, LINC00624, ZNF655, LINC02198, RP3_337O189,
CNTNAP4, RP11-517H2.6, MTND5P16, ACAD10, LOC728975, FKBP3,
PPP2R2B, RP11_299G205, LOC400710, RP11_429P32, RP11_497D63,
LINC01270, IGFBP3, DNPEP, RP1_125I34, RP11_312J185, TPST2,
MYL2, TAGAP, MIDN, RP11_111F52, FAM171A1, LINC00671, CLDN6,
RP11_53I64, RNU6-1196P, RP11_299G202, ZNF514, SDCBP2P1,
FAM204A, AP0002556, AC0040143, PRR26, MLLT6, MARCHF5,
MAPK8IP1, ADAMTS12, RP11_631N164, SUDS3P1, FIRRE,
RP11_9E171, DNAJA3, LOC101929592, DACT3-AS1, TNF,
RP11_514P82, TNFRSF11B, IKBI</td>
                <td rowspan="1" colspan="1">ADCYAP1, ADGRB1, BCAR3, caspase, CCL27, CLEC11A, DNAJA3,
ERK, ERK1/2, FBXO31, FIRRE, FXN, HCG11, Histone h3, Hsp90,
HTR4, IGFBP3, IL17RD, KLF2, MAP4K4, MAPK8IP1, NEU1, P2RY6,
P38 MAPK, PPP2R2B, RBM17, SLC8A1, SND1-BRAF, SP7, STK10,
SYK, SYNPO, TAGAP, TNF, TNFRSF11B</td>
                <td rowspan="1" colspan="1">10^−20</td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1">[Connective tissue disorders, organismal injury and
abnormalities, skeletal and muscular disorders]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TCGA-COAD</td>
                <td rowspan="1" colspan="1">ZNF266, IZUMO1, ORM2, RPSAP4, DDX50P1, PABPC1P3, ZNF767P,
RP5-1056L3.3, U4792429, RALGAPB, RP11_15B245,
RP4_665J23,</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">No significant network</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <fig position="float" id="fig2-11769351221127875">
        <label>Figure 2.</label>
        <caption>
          <p>AUC-ROC results as a function of the features numbers for 3 datasets:
TCGA selected model data, CPTAC3-ccRCC, and CPTAC3-UCEC. The datasets
were tested on each model and AUC-ROC score was calculated. The blue
line represents the average AUC-ROC for all 500 results of the TCGA
dataset.</p>
        </caption>
        <graphic xlink:href="10.1177_11769351221127875-fig2" position="float"/>
      </fig>
      <p>The code for the models creation pipelines can be downloaded from <ext-link xlink:href="https://github.com/omrin/surviveai" ext-link-type="uri">https://github.com/omrin/surviveai</ext-link>.</p>
    </sec>
    <sec id="section9-11769351221127875">
      <title>Results</title>
      <sec id="section10-11769351221127875">
        <title>AUC-ROC mean of over 80% was achieved in 5 projects</title>
        <p>Out of 26 RNA-Seq TCGA-tumor type projects, only 14 had the required ratio
between group size and the total number of samples (20%-80%) and had a
minimum of 30 samples.</p>
        <p>An average AUC-ROC score was calculated for the last 500 models (features
range from 1 to 500). Out of the 15 cancer types, 5 tumor groups had an
average AUC-ROC of over 80% TCGA-LGG (low grade glioma) 0.92 AUC-ROC,
TCGA-COAD (colon adenocarcinoma) 0.84 AUC-ROC, TCGA-SARC (sarcoma) 0.86
AUC-ROC, TCGA-CESC (cervical squamous cell carcinoma and endocervical
adenocarcinoma) 0.8 AUC-ROC, and TCGA-KIRP (kidney renal papillary cell
carcinoma) 0.88 AUC-ROC. Detailed results and statistics for each TCGA
project can be found at <xref rid="table1-11769351221127875" ref-type="table">Table 1</xref>.</p>
        <p>The model with the minimal features that most closely predicted the
calculated AUC-ROC average was selected (See <xref rid="fig2-11769351221127875" ref-type="fig">Figure 2</xref>). Each selected model used
dozens of dimensions: a maximum of 90 features for TCGA-LGG and minimum 12
features for TCGA-COAD.</p>
      </sec>
      <sec id="section11-11769351221127875">
        <title>Prediction of the top 5 models highly correlates with sample tumor
origin</title>
        <p>The top 5 models were tested on all 15 TCGA project sample datasets. AUC-ROC
scores were calculated for each dataset using the predictions of each sample
and the known final results, see heatmap in <xref rid="table3-11769351221127875" ref-type="table">Table 3</xref>. As expected, the scores
for the training samples that were used to create prediction models were
high and close to 1. For other datasets, the predictions were almost without
correlation to the true condition of the samples (score .5)</p>
        <table-wrap position="float" id="table3-11769351221127875">
          <label>Table 3.</label>
          <caption>
            <p>Each data set was tested on top 5 models. The AUC-ROC score was
calculated based on the predictions rate for each dataset.</p>
          </caption>
          <alternatives>
            <graphic xlink:href="10.1177_11769351221127875-table3" position="float"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
                <col align="char" char="." span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" colspan="5" rowspan="1">Prediction model</th>
                </tr>
                <tr>
                  <th align="left" rowspan="1" colspan="1">CESC</th>
                  <th align="left" rowspan="1" colspan="1">COAD</th>
                  <th align="left" rowspan="1" colspan="1">KIRP</th>
                  <th align="left" rowspan="1" colspan="1">LGG</th>
                  <th align="left" rowspan="1" colspan="1">SARC</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td colspan="7" rowspan="1">
                    <inline-graphic xlink:href="10.1177_11769351221127875-img1.jpg"/>
                  </td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="table-fn1-11769351221127875">
              <p>Red indicates opposite prediction correlation and intensity
ranges between 0 to 0.5. Green indicates direct prediction
correlation and ranges from 0.5 to 1. White indicates that there
is no correlation.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Interestingly, a high negative correlation was found between the prediction
models TCGA-CESC, TCGA-LGG, and TCGA-SARC and the predictions for the
samples of the TCGA-READ project.</p>
      </sec>
      <sec id="section12-11769351221127875">
        <title>Correlation of outcome predictions of TCGA dataset analyses with the
validation datasets within tumor types</title>
        <p>In addition to the validation of the predictions obtained by analysis of the
TCGA training sets using the testing sets, we further validated the models
using 2 independent datasets that served for measuring the robustness of the
models. We chose CPTAC3-ccRCC renal tumor dataset for the validation of a
model developed for the same tissue of origin tumor which had a high
prediction score, and CPTAC3-UCEC uterine tumor as an independent dataset
for the testing of our model for the analysis of a tumor type where specific
prediction model had a lower score.</p>
        <p>The AUC-ROC obtained by the application of the TCGA-KIRP based model for the
analysis of the CPTAC3-ccRCC data was 0.86, very similar to the value 0.88
of the TCGA-KIRP test group. Interestingly, TCGA renal cell tumors have 2
sub-types: Kidney renal clear cell carcinoma (TCGA-KIRC) and Kidney renal
papillary cell carcinoma (TCGA-KIRP). We analyzed these subtypes separately
and the predictions were 0.79 and 0.88 AUC-ROC for the test groups,
respectively. When we applied these 2 prediction models for validation
cohort CPTAC3-ccRCC, which contains clear cell renal cell tumors, the
predictions of both models were similar, 0.77 and 0.86 AUC-ROC,
respectively. The prediction of the less efficient TCGA-UCEC model for the
CPTAC3-UCEC data indeed gave a low predictions score, 0.63. Surprisingly the
tissue discordant TCGA-KIRP prediction model for the analysis of uterine the
CPTAC3-UCEC data set over performed the prediction of the tissue concordant
TCGA-UCEC model and scored AUC-ROC 0.663. Finally, we have tested all the
TCGA predictions models using renal CPTAC3-ccRCC dataset. For most of the
models, the results were below 0.7, except for the TCGA-SARC model which was
0.85. When we used the uterine CPTAC3-UCEC dataset on all the TCGA
prediction models, all the scores were very low except for the TCGA-SARC
model which was 0.74.</p>
      </sec>
      <sec id="section13-11769351221127875">
        <title>TCGA-KIRP model accurately predicted the prognosis of CPTAC3-ccRCC
samples, but on a different scale</title>
        <p>We analyzed the RNA-SEQ data of CPTAC3-ccRCC samples using the selected
TCGA-KIRP final model (created using 42 features as described in <xref rid="table2-11769351221127875" ref-type="table">Table 2</xref>). The
mean scores for the Deceased and Tumor-free groups were significantly
different as shown in <xref rid="fig3-11769351221127875" ref-type="fig">Figure 3</xref>, however, the scale by which each group was measured
also differed. For the TCGA-KIRP samples, the model produced scores between
0.025 and 0.95 while the CPTAC3-ccRCC sample scores were 0.18 to 0.425
(before normalization to 1). The model prediction AUC-ROC score for the
CPTAC3-ccRCC was 0.86, almost identical to the TCGA-KIRP testing set.</p>
        <fig position="float" id="fig3-11769351221127875">
          <label>Figure 3.</label>
          <caption>
            <p>Mean score results from TCGA-KIRP model on TCGA-KIRP and CPTAC3-ccRCC
groups, deceased, and tumor free.
†<italic toggle="yes">P</italic>-value = 2.23 × 10<sup>−54</sup>.
‡<italic toggle="yes">P</italic>-value = .01.</p>
          </caption>
          <graphic xlink:href="10.1177_11769351221127875-fig3" position="float"/>
        </fig>
      </sec>
      <sec id="section14-11769351221127875">
        <title>Pathway analysis revealed enrichment for cancer and cancer-related
canonical pathways</title>
        <p>We used the Ingenuity Pathway Analysis (IPA) to analyze the genes selected in
the final model for enrichment of related pathways. The top pathways were
those involved in basic functions related to tumorigenesis and organ
development. For example, in the TCGA-KIRP tumor prognosis prediction model,
the pathways of Cell Cycle, Connective Tissue Development and Function, and
Renal and Urological System Development and Function were the most highly
enriched with a <italic toggle="yes">P</italic>-value of 10<sup>−38</sup>. In the
TCGA-CESC, the highly represented pathways were Inflammatory Diseases as
well as Inflammatory Response and Organismal Injury and Abnormalities. Due
to the fact that cervical cancer is usually related to the effect of the
human papillomavirus, it is not surprising that the genes associated with an
inflammatory response may influence the prognosis of the cancer in those
patients.<sup><xref rid="bibr14-11769351221127875" ref-type="bibr">14</xref></sup> The TCGA-SARC model genes are enriched in Cell
Cycle, Cell Death and Survival, and Cellular Development pathways which are
relevant to cancer progression and prognosis. The LGG model genes are
enriched in pathways involved in Organismal Injury and Abnormality, which
are related to tumor microenvironment inflammation which was recently linked
to these tumors.<sup><xref rid="bibr15-11769351221127875" ref-type="bibr">15</xref></sup> A full list of the features of the models used,
pathway nodes, scores, and pathways functions can be seen in <xref rid="table2-11769351221127875" ref-type="table">Table 2</xref>.</p>
        <p>As expected, functional pathways related to the tissues of origin such as
Renal and Urological System Development and Function, Reproductive System
Disease, and Connective Tissue Disorders correlated to the primary tissue of
the TCGA prediction models: kidney, cervix and glial cells,
respectively.</p>
      </sec>
      <sec id="section15-11769351221127875">
        <title>Comparison of gene enrichment of 2 prediction models for the same samples
cohort</title>
        <p>We developed, based on the analysis of the same set of TCGA-KIRP samples, 2
separate models based on 300-feature model and 42-feature model. The
predictions of the 2 models were 0.85 and 0.86, respectively. The 42 genes
that comprised the smaller prediction model are included in the 300 genes
model. Analysis of the 300 features TCGA-KIRP model by the Ingenuity
Pathways Analysis software matched 7 networks that are significantly
enriched by those genes (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/11769351221127875" ext-link-type="uri">Supplemental Table 3</ext-link> for specific molecules in each network
and <italic toggle="yes">P</italic>-values). The most enriched network
(<italic toggle="yes">P</italic>-value = 10<sup>−45</sup>) that was selected by the
IPA is composed of 35 components, out of them 26 are shared with the 300
features of the model. The network is related to the following functions:
Cancer, Organismal Injury and Abnormalities, and Reproductive System
Disease. In the 42 feature TCGA-KIRP model on the other hand the most
enriched network (<italic toggle="yes">P</italic>-value = 10<sup>−38</sup>) is also
composed of 35 genes, out of them 15 genes are shared with the 42 features
of the model. Cell Cycle, Connective Tissue Development and Function, and
Renal and Urological System Development and Function pathways categories
were significantly enriched in this network. As depicted in <xref rid="fig4-11769351221127875" ref-type="fig">Figure 4</xref>, only 5
genes from the 42 feature TCGA-KIRP model were characterized as IPA network
nodes in the larger network: DMBT1, IL11, HOXB6, TRIB3, PIM1. Those genes
appear in both networks and might play a significant role in the disease
renal cancer prognosis.</p>
        <fig position="float" id="fig4-11769351221127875">
          <label>Figure 4.</label>
          <caption>
            <p>Shared features between top networks of TCGA-KIRP prediction models:
(A) The top network from IPA prediction for the TCGA-KIRP 300
features model. That network is associated with Cancer, Organismal
Injury and Abnormalities, Reproductive System Disease pathways. The
gray nodes are the nodes from the model feature list (26 out of 35
network nodes, <italic toggle="yes">P</italic>-value = 10<sup>−42</sup>). (B) The
top network from IPA prediction for the TCGA-KIRP 42 features model.
That network is associated with Cell Cycle, Connective Tissue
Development and Function, Renal and Urological System Development
and Function. The gray nodes are the nodes from the model feature
list (15 out of 35 network nodes,
<italic toggle="yes">P</italic>-value = 10<sup>−38</sup>). The blue nodes are
the shared genes between the networks that are also features in both
models: DMBT1, IL11, HOXB6, TRIB3, PIM1.</p>
          </caption>
          <graphic xlink:href="10.1177_11769351221127875-fig4" position="float"/>
        </fig>
        <p>DMBT1<sup>16</sup> (Deleted In Malignant Brain Tumors 1) is a tumor
suppressor gene. Deletions in this gene play a role in the progression of
many human cancers, including brain, lung, esophageal, gastric, and
colorectal tumors. IL11, as part of KRT8-IL11 axis activation
upregulation,<sup><xref rid="bibr17-11769351221127875" ref-type="bibr">17</xref></sup> promotes tumor
metastasis and is predictive of a poor prognosis in renal cell carcinoma. It
was also suggested as a potential therapeutic target in cancer
treatment.<sup><xref rid="bibr18-11769351221127875" ref-type="bibr">18</xref></sup> HOXB6 (Homeobox B6) was found to play different
roles in several cancer pathways,<sup><xref rid="bibr19-11769351221127875" ref-type="bibr">19</xref>,<xref rid="bibr20-11769351221127875" ref-type="bibr">20</xref></sup> including in
methylation-driven genes related to prognosis in renal cell
carcinoma.<sup><xref rid="bibr21-11769351221127875" ref-type="bibr">21</xref></sup> TRIB3 (Tribbles pseudokinase 3) has many biological
functions. However, high expression of TRIB3 was correlated with both
advanced tumor stage and unfavorable prognosis.<sup><xref rid="bibr22-11769351221127875" ref-type="bibr">22</xref></sup> High expression of
TRIB3 in other cancer types, such as hepatocellular carcinoma and lung
cancer, also correlated with poor survival rate.<sup><xref rid="bibr23-11769351221127875" ref-type="bibr">23</xref>,<xref rid="bibr24-11769351221127875" ref-type="bibr">24</xref></sup> PIM1 is a
proto-oncogene belonging to the Ser/Thr protein kinase family. It was
recently found that when overexpressed in human renal cell carcinoma tissues
and cell lines, it positively correlated with disease progression.<sup><xref rid="bibr25-11769351221127875" ref-type="bibr">25</xref></sup> PIM1
was found to be involved in Smad2, Smad3, and c-Myc<sup><xref rid="bibr26-11769351221127875" ref-type="bibr">26</xref></sup>
phosphorylation and was suggested as a potential therapeutic target for
renal cell carcinoma patients.</p>
      </sec>
      <sec id="section16-11769351221127875">
        <title>SurviveAI webapp</title>
        <p>An interactive free software based on the models was created using Flask
1.1.2. It enables physicians and researchers to get clinical predictions
(for research purposes only) for RNA-Seq cancer multiple samples. The easy
to use interface allows one to insert specific gene lists with FPKM-UQ
values for each gene and to get predicted survival scores for 5 cancer
types: Cervical squamous cell carcinoma and endocervical adenocarcinoma
(CESC), colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma
(KIRP), brain lower grade glioma (LGG) and sarcoma (SARC). The tool uses
scikit-learn’s <italic toggle="yes">predict_proba(X)</italic> method in the chosen
TCGA-project model, and provides the probability for the given sample to
match each group. Higher scores correlated with higher survival likelihood,
while lower scores suggest poor survival prognosis. That being said, it is
essential to calibrate the prediction scores scale for each cohort before
using the tool as a predictor for specific samples, due high batch effect
sensitivity of the models. In <xref rid="fig3-11769351221127875" ref-type="fig">Figure 3</xref> demonstrate the difference
in the mean score value for each group. Although the CPTAC3-ccRCC difference
between the Deceased and Tumor-free groups is significant
(<italic toggle="yes">P</italic>-value = .01), it is less significant than the
TCGA-KIRP group (<italic toggle="yes">P</italic>-value = 2.23 × 10<sup>−54</sup>).
Calibration should be done with at least 10 to 20 samples to get maximum
accuracy. The app automatically normalizes the scores to 1 by dividing them
using the highest result.</p>
        <p>SurviveAI webapp can be accessed at <ext-link xlink:href="https://tinyurl.com/surviveai" ext-link-type="uri">https://tinyurl.com/surviveai</ext-link></p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="section17-11769351221127875">
    <title>Discussion</title>
    <p>Following the significant price decrease of high-throughput sequencing, projects like
TCGA have generated vast amounts of data that enable machine learning. Usually, only
specific types of cancer cohorts are used to create prediction models, combining
multiple sources of OMICs-data to enhance AUC-ROC-based predictions. A multi-OMICs
prediction model is more costly and less useful for routine clinical use, due to the
increased number of methodologies needed. In order for a model to be user friendly
and readily applicable, we based our model on RNA-seq data only, which is affordable
and accessible, in clinical and research facilities. We have used 70% of the samples
in each TCGA project to train the prediction models, and in order to validate the
prediction, we tested them against the rest 30% of the samples from the cohort that
was not used for training (test data). In addition, the models were tested against
external datasets, CPTAC3-ccRCC and CPTAC3-UCEC. As expected, the models provided
low prediction scores for the CPTAC3-UCEC samples, as none of the models were
related to uterus cancer. Although KIRP (Kidney Renal Papillary Cell Carcinoma) and
ccRCC (Clear cell renal cell carcinoma) are different subtypes of kidney cancer, the
TCGA-KIRP model provides excellent predictions (AUC-ROC = 0.86) for the ccRCC
dataset samples. Interestingly, the TCGA-SARC model also provides about the same
accuracy (AUC-ROC = 0.85) for this dataset, even though the 2 models (KIRP and SARC)
do not share any features at all (see <xref rid="table2-11769351221127875" ref-type="table">Table 2</xref>)</p>
    <p>We highly recommend that before using the models to calibrate with a truth set that
contains at least 10 to 20 samples, as RNA expression level tends to be sensitive to
batch effect.</p>
    <p>For example, the CPTAC3-ccRCC Tumor-Free samples produce average score results of
0.73 for the Tumor-Free samples while the TCGA-KIRP survived results were between
0.9 and 1 (<xref rid="table3-11769351221127875" ref-type="table">Table
3</xref>).</p>
    <p>In this study, we show a novel method of machine learning driven pathways discovery
using the simple and robust technique of reverse feature elimination. Also, the
decision to use 2 distinct groups (Deceased and Tumor free), allowed us to decipher
critical genes and features that are important for progression prediction in some of
the projects.</p>
    <p>We checked all possible projects available for analysis on the TCGA datasets and used
only RNA-seq data for predictions. The reason for this is the relatively low cost
and simplicity to produce such data for clinical and research purposes. This allows
other researchers to use the models available free online. The Random Forest model
is simple and allows us to easily extract the most important features from the
data.</p>
    <p>In 4 out of 5 models, a significant portion of the models’ genes were part of
cancer-related pathways. The molecules which were not included might be extensions
of those networks or create another unknown network themselves. From a clinical
perspective those genes might serve as new drug targets or biomarkers.</p>
  </sec>
  <sec sec-type="supplementary-material" id="section18-11769351221127875" specific-use="figshare">
    <title>Supplemental Material</title>
    <supplementary-material id="suppl1-11769351221127875" position="float" content-type="local-data">
      <caption>
        <title>sj-xlsx-1-cix-10.1177_11769351221127875 – Supplemental material for
SurviveAI: Long Term Survival Prediction of Cancer Patients Based on Somatic
RNA-Seq Expression</title>
      </caption>
      <media xlink:href="sj-xlsx-1-cix-10.1177_11769351221127875.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, sj-xlsx-1-cix-10.1177_11769351221127875 for SurviveAI:
Long Term Survival Prediction of Cancer Patients Based on Somatic RNA-Seq
Expression by Omri Nayshool, Nitzan Kol, Elisheva Javaski, Ninette Amariglio and
Gideon Rechavi in Cancer Informatics</p>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>The results shown here are in whole or part based upon data generated by the TCGA
Research Network: <ext-link xlink:href="https://www.cancer.gov/tcga" ext-link-type="uri">https://www.cancer.gov/tcga</ext-link>."</p>
  </ack>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p>
    </fn>
    <fn fn-type="COI-statement">
      <p>The author(s) declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: GR is a
consultant to Pangea Biomed.</p>
    </fn>
    <fn fn-type="con">
      <p><bold>Author Contributions:</bold> ON designed the project, collected and analysed the data; NK and EJ contributed
to data analysis; NA contributed to the manuscript design and editing; GR
supervised and mentored the project.</p>
    </fn>
    <fn fn-type="other">
      <p><bold>ORCID iD:</bold> Omri Nayshool <inline-graphic xlink:href="10.1177_11769351221127875-img2.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-5060-891X" ext-link-type="uri">https://orcid.org/0000-0001-5060-891X</ext-link></p>
    </fn>
    <fn fn-type="supplementary-material">
      <p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="bibr1-11769351221127875">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Colombet</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>. <article-title>Estimating the global cancer
incidence and mortality in 2018: GLOBOCAN sources and
methods</article-title>. <source>Int J Cancer</source>.
<year>2019</year>;<volume>144</volume>:<fpage>1941</fpage>-<lpage>1953</lpage>.<pub-id pub-id-type="pmid">30350310</pub-id></mixed-citation>
    </ref>
    <ref id="bibr2-11769351221127875">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname><given-names>M.</given-names></name></person-group><article-title>Biomarkers for personalized oncology: recent advances and future
challenges</article-title>. <source>Metabolism</source>.
<year>2015</year>;<volume>64</volume>:S16-S21.</mixed-citation>
    </ref>
    <ref id="bibr3-11769351221127875">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzi</surname><given-names>M</given-names></name><name><surname>Parkl</surname><given-names>M</given-names></name><name><surname>Phanl</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>MD.</given-names></name></person-group><article-title>Integration of multimodal RNA-seq data for prediction of kidney
cancer survival</article-title>. <source>Proceedings (IEEE Int Conf
Bioinformatics Biomed)</source>.
<year>2015</year>;<volume>2015</volume>:<fpage>1591</fpage>-<lpage>1595</lpage>.<pub-id pub-id-type="pmid">27532026</pub-id></mixed-citation>
    </ref>
    <ref id="bibr4-11769351221127875">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>. <article-title>Six-gene signature for
predicting survival in patients with head and neck squamous cell
carcinoma</article-title>. <source>Aging</source>.
<year>2020</year>;<volume>12</volume>:<fpage>767</fpage>-<lpage>783</lpage>.<pub-id pub-id-type="pmid">31927533</pub-id></mixed-citation>
    </ref>
    <ref id="bibr5-11769351221127875">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>TS</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>. <article-title>Deep learning-based cancer
survival prognosis from RNA-seq data: approaches and
evaluations</article-title>. <source>BMC Med Genomics</source>.
<year>2020</year>;<volume>13</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">32241264</pub-id></mixed-citation>
    </ref>
    <ref id="bibr6-11769351221127875">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name></person-group><article-title>Identification of a sixteen-gene prognostic biomarker for lung
adenocarcinoma using a machine learning method</article-title>. <source>J
Cancer</source>.
<year>2020</year>;<volume>11</volume>:<fpage>1288</fpage>-<lpage>1298</lpage>.<pub-id pub-id-type="pmid">31956375</pub-id></mixed-citation>
    </ref>
    <ref id="bibr7-11769351221127875">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W-Z</given-names></name><name><surname>Guo</surname><given-names>L-M</given-names></name><name><surname>Xu</surname><given-names>T-Q</given-names></name><name><surname>Yin</surname><given-names>Y-H</given-names></name><name><surname>Jia</surname><given-names>F.</given-names></name></person-group><article-title>Identification of a multidimensional transcriptome signature for
survival prediction of postoperative glioblastoma multiforme
patients</article-title>. <source>J Transl Med</source>.
<year>2018</year>;<volume>16</volume>:<fpage>368</fpage>.<pub-id pub-id-type="pmid">30572911</pub-id></mixed-citation>
    </ref>
    <ref id="bibr8-11769351221127875">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milanez-Almeida</surname><given-names>P</given-names></name><name><surname>Martins</surname><given-names>AJ</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name><name><surname>Tsang</surname><given-names>JS.</given-names></name></person-group><article-title>Cancer prognosis with shallow tumor RNA
sequencing</article-title>. <source>Nat Med</source>.
<year>2020</year>;<volume>26</volume>:<fpage>188</fpage>-<lpage>192</lpage>.<pub-id pub-id-type="pmid">32042193</pub-id></mixed-citation>
    </ref>
    <ref id="bibr9-11769351221127875">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breiman</surname><given-names>L.</given-names></name></person-group><article-title>Random forests</article-title>. <source>Mach Learn</source>.
<year>2001</year>;<volume>45</volume>:<fpage>5</fpage>-<lpage>32</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr10-11769351221127875">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Probst</surname><given-names>P</given-names></name><name><surname>Hornung</surname><given-names>R</given-names></name><name><surname>Jurinovic</surname><given-names>V</given-names></name><name><surname>Boulesteix</surname><given-names>A-L.</given-names></name></person-group><article-title>Large-scale benchmark study of survival prediction methods using
multi-omics data</article-title>. <source>Brief Bioinform</source>.
<year>2021</year>;<volume>22</volume>:bbaa167. doi:<pub-id pub-id-type="doi">10.1093/bib/bbaa167</pub-id></mixed-citation>
    </ref>
    <ref id="bibr11-11769351221127875">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valk</surname><given-names>PJM</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Beijen</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Prognostically useful
gene-expression profiles in acute myeloid leukemia</article-title>.
<source>New Engl J Med</source>.
<year>2004</year>;<volume>350</volume>:<fpage>1617</fpage>-<lpage>1628</lpage>.<pub-id pub-id-type="pmid">15084694</pub-id></mixed-citation>
    </ref>
    <ref id="bibr12-11769351221127875">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kela</surname><given-names>I</given-names></name><name><surname>Ein-Dor</surname><given-names>L</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Givol</surname><given-names>D</given-names></name><name><surname>Domany</surname><given-names>E.</given-names></name></person-group><article-title>Outcome signature genes in breast cancer: is there a unique
set?</article-title><source>Breast Cancer Res</source>.
<year>2005</year>;<volume>7</volume>:<volume>4</volume>.<fpage>38</fpage>.</mixed-citation>
    </ref>
    <ref id="bibr13-11769351221127875">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyon</surname><given-names>I</given-names></name><name><surname>Weston</surname><given-names>J</given-names></name><name><surname>Barnhill</surname><given-names>S</given-names></name><name><surname>Vapnik</surname><given-names>V.</given-names></name></person-group><article-title>Gene selection for cancer classification using support vector
machines</article-title>. <source>Mach Learn</source>.
<year>2002</year>;<volume>46</volume>:<fpage>389</fpage>-<lpage>422</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr14-11769351221127875">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adefuye</surname><given-names>A</given-names></name><name><surname>Sales</surname><given-names>K.</given-names></name></person-group><article-title>Regulation of inflammatory pathways in cancer and infectious
disease of the cervix</article-title>. <source>Scientifica</source>.
<year>2012</year>;<volume>2012</volume>. doi:0</mixed-citation>
    </ref>
    <ref id="bibr15-11769351221127875">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelson</surname><given-names>N</given-names></name><name><surname>Rincon-Torroella</surname><given-names>J</given-names></name><name><surname>Quiñones-Hinojosa</surname><given-names>A</given-names></name><name><surname>Greenfield</surname><given-names>JP.</given-names></name></person-group><article-title>Exploring the role of inflammation in the malignant
transformation of low-grade gliomas</article-title>. <source>J
Neuroimmunol</source>.
<year>2016</year>;<volume>297</volume>:<fpage>132</fpage>-<lpage>140</lpage>.<pub-id pub-id-type="pmid">27397086</pub-id></mixed-citation>
    </ref>
    <ref id="bibr16-11769351221127875">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>J</given-names></name><name><surname>Wiemann</surname><given-names>S</given-names></name><name><surname>Scheurlen</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>. <article-title>DMBT1, a new member of the
SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain
tumours</article-title>. <source>Nat Genet</source>.
<year>1997</year>;<volume>17</volume>:<fpage>32</fpage>-<lpage>39</lpage>.<pub-id pub-id-type="pmid">9288095</pub-id></mixed-citation>
    </ref>
    <ref id="bibr17-11769351221127875">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>H-S</given-names></name><name><surname>Jiang</surname><given-names>WH</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>. <article-title>KRT8 upregulation promotes
tumor metastasis and is predictive of a poor prognosis in clear cell renal
cell carcinoma</article-title>. <source>Oncotarget</source>.
<year>2017</year>;<volume>8</volume>:<fpage>76189</fpage>-<lpage>76203</lpage>.<pub-id pub-id-type="pmid">29100303</pub-id></mixed-citation>
    </ref>
    <ref id="bibr18-11769351221127875">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>DH</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wakefield</surname><given-names>MR</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name></person-group><article-title>The role of IL-11 in immunity and cancer</article-title>.
<source>Cancer Lett</source>.
<year>2016</year>;<volume>373</volume>:<fpage>156</fpage>-<lpage>163</lpage>.<pub-id pub-id-type="pmid">26826523</pub-id></mixed-citation>
    </ref>
    <ref id="bibr19-11769351221127875">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vider</surname><given-names>BZ</given-names></name><name><surname>Zimber</surname><given-names>A</given-names></name><name><surname>Chastre</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Deregulated expression of
homeobox-containing genes, HOXB6, B8, C8, C9, and Cdx-1, in human colon
cancer cell lines</article-title>. <source>Biochem Biophys Res
Commun</source>.
<year>2000</year>;<volume>272</volume>:<fpage>513</fpage>-<lpage>518</lpage>.<pub-id pub-id-type="pmid">10833444</pub-id></mixed-citation>
    </ref>
    <ref id="bibr20-11769351221127875">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>A.</given-names></name></person-group><article-title>ST8SIA6-AS1 promotes hepatocellular carcinoma by absorbing
miR-5195-3p to regulate HOXB6</article-title>. <source>Cancer Biol
Ther</source>.
<year>2020</year>;<volume>21</volume>:<fpage>647</fpage>-<lpage>655</lpage>.<pub-id pub-id-type="pmid">32420798</pub-id></mixed-citation>
    </ref>
    <ref id="bibr21-11769351221127875">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>. <article-title>Identification of
methylation-driven genes related to prognosis in clear-cell renal cell
carcinoma</article-title>. <source>J Cell Physiol</source>.
<year>2020</year>;<volume>235</volume>:<fpage>1296</fpage>-<lpage>1308</lpage>.<pub-id pub-id-type="pmid">31273792</pub-id></mixed-citation>
    </ref>
    <ref id="bibr22-11769351221127875">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. <article-title>TRIB3 promotes the
proliferation and invasion of renal cell carcinoma cells via activating MAPK
signaling pathway</article-title>. <source>Int J Biol Sci</source>.
<year>2019</year>;<volume>15</volume>:<fpage>587</fpage>-<lpage>597</lpage>.<pub-id pub-id-type="pmid">30745845</pub-id></mixed-citation>
    </ref>
    <ref id="bibr23-11769351221127875">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X-J</given-names></name><name><surname>Li</surname><given-names>F-F</given-names></name><name><surname>Zhang</surname><given-names>Y-J</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>W-H.</given-names></name></person-group><article-title>TRIB3 promotes hepatocellular carcinoma growth and predicts poor
prognosis</article-title>. <source>Cancer Biomark</source>.
<year>2020</year>;<volume>29</volume>:<fpage>307</fpage>-<lpage>315</lpage>.<pub-id pub-id-type="pmid">32716348</pub-id></mixed-citation>
    </ref>
    <ref id="bibr24-11769351221127875">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>MB.</given-names></name></person-group><article-title>TRIB3 promotes lung cancer progression by activating β-catenin
signaling</article-title>. <source>Eur J Pharmacol</source>.
<year>2019</year>;<volume>863</volume>:<fpage>172697</fpage>.<pub-id pub-id-type="pmid">31562867</pub-id></mixed-citation>
    </ref>
    <ref id="bibr25-11769351221127875">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>PIM1 mediates epithelial-mesenchymal transition by targeting
Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell
carcinoma oncogenesis</article-title>. <source>Cell Death Dis</source>.
<year>2018</year>;<volume>9</volume>:<fpage>307</fpage>.<pub-id pub-id-type="pmid">29472550</pub-id></mixed-citation>
    </ref>
    <ref id="bibr26-11769351221127875">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Roh</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Pim1 kinase synergizes with
c-MYC to induce advanced prostate carcinoma</article-title>.
<source>Oncogene</source>.
<year>2010</year>;<volume>29</volume>:<fpage>2477</fpage>-<lpage>2487</lpage>.<pub-id pub-id-type="pmid">20140016</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
